Introduction
Methods
Patient data collection
Immunohistochemistry
Statistical analyses
Results
Characterization of patients and study summary
Tumor stage | Before NAC | After NAC | ||||||
T0 | T1 | T2 | T3 | T0 | T1 | T2 | T3 | |
0 | 19 | 131 | 39 | 30 | 61 | 69 | 29 | |
Histopathology | Ductal | Lobular | Others | |||||
179 | 3 | 7 | ||||||
Involvement of lymph nodes | Before NAC | After NAC | ||||||
Yes | No | Yes | No | |||||
129 | 60 | 112 | 77 | |||||
Type of NAC | Cytotoxic | Cytotoxic + trastuzumab or Cytotoxic + trastuzumab + patozumab | ||||||
163 | 26 |
Tumor size reduction after receiving NAC
pCR | non-pCR | Test | n | p-value | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
HER2 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | Chi-square | 189 | <0.001* |
3 | 2 | 2 | 19 | 13 | 43 | 64 | 43 | ||||
ER | - | + | - | + | Chi-square | 189 | <0.001* | ||||
23 | 3 | 41 | 122 | ||||||||
PR | - | + | - | + | Chi-square | 189 | <0.001* | ||||
25 | 1 | 49 | 114 | ||||||||
TOPO II | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | Chi-square for Ordinal Data | 118 | 0.03* |
0 | 2 | 5 | 2 | 1 | 58 | 43 | 7 | ||||
EGFR | - | + | ++ | +++ | - | + | ++ | +++ | Chi-square | 120 | <0.001* |
1 | 1 | 6 | 1 | 52 | 39 | 16 | 4 | ||||
Ki67 | Mean = 52.81 | Mean = 36.40 | Mann-Whitney U | 189 | <0.001* | ||||||
CK5/6 | - | + | - | + | Chi-square | 116 | 0.23 | ||||
4 | 3 | 84 | 25 | ||||||||
AR | Mean = 42.7 | Mean = 35.80 | Mann-Whitney U | 134 | 0.78 | ||||||
p53 | Mean = 43.88 | Mean = 26.86 | Mann-Whitney U | 119 | 0.07 | ||||||
Tumor size | Mean = 2.75 cm | Mean = 3.94 cm | Mann-Whitney U | 189 | <0.001* |
Comparison of biomarker status between pCR and non-pCR patients
Relationship between the tumor size change and biomarker status
Test | n | Coefficient | p-value | |
---|---|---|---|---|
HER2 | Linear regression for dummy variable | 189 | Not significant | > 0.2 |
ER | Linear regression for dummy variable | 189 | 0.3184 | < 0.001* |
PR | Linear regression for dummy variable | 189 | 0.2821 | < 0.001* |
TOPO II | Linear regression for dummy variable | 118 | Not significant | > 0.2 |
EGFR | Linear regression for dummy variable | 120 | Not significant | > 0.05 |
Ki67 | Linear regression | 189 | -0.0044 | 0.003* |
CK5/6 | Linear regression for dummy variable | 116 | Not significant | > 0.05 |
AR | Linear regression | 134 | Not significant | > 0.5 |
P53 | Linear regression | 119 | Not significant | > 0.2 |
Comparison of biomarkers status change after NAC
Before NAC | After NAC | Test | n | p-value | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HER2 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | Chi-square | 143 | 0.072 | ||||||
11 | 37 | 61 | 34 | 3 | 51 | 57 | 32 | ||||||||||
ER | Mean = 52.42 | Mean = 49.36 | Wilcoxon | 146 | 0.039* | ||||||||||||
ER | - | + | - | + | Chi-square | 146 | 0.58 | ||||||||||
32 | 114 | 36 | 110 | ||||||||||||||
PR | Mean = 31.45 | Mean = 22.28 | Wilcoxon | 146 | 0.013* | ||||||||||||
PR | - | + | - | + | Chi-square | 146 | 0.52 | ||||||||||
41 | 105 | 46 | 100 | ||||||||||||||
TOPO II | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | Chi-square | 84 | 0.041* | ||||
1 | 43 | 35 | 5 | 0 | 4 | 53 | 18 | 8 | 1 | ||||||||
EGFR | - | + | ++ | +++ | - | + | ++ | +++ | Chi-square | 88 | 0.73 | ||||||
45 | 31 | 9 | 3 | 47 | 29 | 11 | 1 | ||||||||||
Ki67 | Mean = 35.28 | Mean = 27.18 | Wilcoxon | 145 | <0.001* | ||||||||||||
CK5/6 | - | + | - | + | Chi-square | 86 | 0.22 | ||||||||||
68 | 18 | 61 | 25 | ||||||||||||||
AR | Mean = 33.30 | Mean = 29.67 | Wilcoxon | 99 | 0.22 | ||||||||||||
p53 | Mean = 25.32 | Mean = 25.68 | Wilcoxon | 87 | 0.93 |